TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $9.00.

A number of analysts have issued reports on HURA shares. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating on the stock. Citigroup started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating on the stock. Citizens Jmp started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st.

TuHURA Biosciences Stock Performance

Shares of NASDAQ HURA opened at $2.08 on Thursday. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.90. The firm’s 50 day moving average price is $2.29 and its 200 day moving average price is $1.61. The firm has a market cap of $132.46 million, a P/E ratio of -3.41 and a beta of 0.01.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). As a group, equities analysts predict that TuHURA Biosciences will post -0.56 EPS for the current year.

Institutional Trading of TuHURA Biosciences

A number of hedge funds have recently added to or reduced their stakes in HURA. Geode Capital Management LLC boosted its stake in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares during the last quarter. Cetera Investment Advisers purchased a new position in shares of TuHURA Biosciences in the 1st quarter worth about $251,000. WealthShield Partners LLC purchased a new position in shares of TuHURA Biosciences in the 1st quarter worth about $164,000. Deutsche Bank AG raised its holdings in shares of TuHURA Biosciences by 209.8% in the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after purchasing an additional 54,051 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in shares of TuHURA Biosciences in the 2nd quarter worth about $97,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.